Stintzing Stintzing S S Miller-Phillips Miller-Phillips L L Modest Modest DP DP Impact of BRAF and RAS mutations on first-line efficacy of folfiri plus cetuximab versus folfiri plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study Impact of BRAF and RAS mutations on first-line efficacy of folfiri plus cetuximab versus folfiri plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study Eur J Cancer Eur J Cancer 2017 2017 79 79 50 50 60 60 10.1016/j.ejca.2017.03.023 10.1016/j.ejca.2017.03.023 supplied-pmid 28463756? The gene discussed is BRAF; the disease is cancer.